Suzetrigine and the Promise of Non-Opioid Pain Relief. At the forefront of Vertex's expansion into pain management is suzetrigine (VX-548), a novel drug candidate with the potential to ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex's stock has risen 18% since last December, ... to believe VK-548's potential in neuropathies is more interesting than its potential in a crowded and complex acute pain management market.

Acute pain is something more than 80 million Americans fill prescriptions to treat each year, according to Vertex. As opposed to chronic pain, which can last well after an injury or illness has ...

Now, let's consider the Vertex and Latigo pain candidates. They both address the problem in the same way, by targeting NaV1.8, a sodium channel that plays a key role in pain signaling.

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... A Promising Non-Opioid Solution to Acute Pain Management. TipRanks. Oct. 21, 2024, 04:55 AM.

Vertex's VX-548 shows promising efficacy and safety in neuropathic pain management, potentially outperforming Lyrica. Read more about VRTX stock here.

Leerink Partners analyst David Risinger maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $600.00. David Risinger has given his Buy ...

Orion will pay Jemincare $15.9 million to develop and commercialize the preclinical, non-opioid pain therapy JMKX000623. Orion inks pain management licensing deal to compete with Vertex Fierce Pharma ...

Vertex is strategically expanding into the pain management sector, Vertex Pharmaceuticals (NASDAQ:VRTX) is a biotechnology company with a strong track record of success in developing treatments ...